Use of combinatorial pharmacogenomic guidance in treating psychiatric disorders.

Aim: To evaluate payer costs associated with treating psychiatric disorders utilizing a combinatorial pharmacogenomics test versus treatment-as-usual (TAU).

Patients & Methods: Administrative claims data were analyzed from health plan members whose treatment was guided by GeneSight Psychotropic testing (CPGx cohort) and those who received TAU (TAU cohort). Reimbursed costs were calculated over the 12-month pre-index and post-index event periods.

Results: 205 CPGx and 478 TAU members were included. Post-index cost savings (US$5505) drove a per-member-per-month savings of US$0.07. Disease-specific analyses resulted in similar savings.

Conclusion: Use of CPGx yielded reduced spending for a commercial health plan across the patient population with psychiatric disorders, as well as among high-cost subpopulations.